Emcure Pharmaceuticals Ltd
Incorporated in 1981, Emcure Pharmaceuticals
Ltd manufactures and markets pharmaceutical products globally[1]
- Market Cap ₹ 19,335 Cr.
- Current Price ₹ 1,020
- High / Low ₹ 1,580 / 889
- Stock P/E 31.8
- Book Value ₹ 217
- Dividend Yield 0.00 %
- ROCE 18.6 %
- ROE 18.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- The company has delivered a poor sales growth of 7.14% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of BSE MidCap BSE IPO Nifty 500 Nifty Smallcap 250 Nifty MidSmallcap 400
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|
| 4,717 | 5,049 | 5,033 | 5,855 | 5,986 | 6,658 | 7,551 | |
| 3,968 | 4,340 | 3,817 | 4,525 | 4,804 | 5,429 | 6,161 | |
| Operating Profit | 749 | 708 | 1,216 | 1,330 | 1,182 | 1,230 | 1,390 |
| OPM % | 16% | 14% | 24% | 23% | 20% | 18% | 18% |
| 72 | -25 | -159 | 63 | 39 | 47 | 67 | |
| Interest | 223 | 257 | 155 | 176 | 214 | 237 | 202 |
| Depreciation | 267 | 321 | 250 | 245 | 260 | 312 | 378 |
| Profit before tax | 331 | 105 | 652 | 973 | 747 | 727 | 878 |
| Tax % | 37% | 4% | 36% | 28% | 25% | 27% | |
| 209 | 101 | 419 | 703 | 562 | 528 | 631 | |
| EPS in Rs | 10.79 | 4.62 | 23.15 | 36.62 | 29.42 | 27.50 | 32.71 |
| Dividend Payout % | 32% | 0% | 4% | 8% | 7% | 7% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 10% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 20% |
| 3 Years: | 6% |
| TTM: | -6% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 24% |
| Last Year: | 18% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 181 | 181 | 181 | 181 | 181 | 181 | 189 |
| Reserves | 1,654 | 1,731 | 2,092 | 1,807 | 2,320 | 2,771 | 3,929 |
| 2,128 | 2,327 | 2,310 | 2,217 | 2,334 | 2,335 | 1,189 | |
| 1,613 | 1,721 | 2,184 | 1,816 | 1,798 | 2,422 | 2,817 | |
| Total Liabilities | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,124 |
| 2,247 | 2,382 | 2,188 | 2,044 | 2,147 | 3,125 | 3,206 | |
| CWIP | 581 | 485 | 302 | 320 | 411 | 159 | 178 |
| Investments | 0 | 0 | 0 | 25 | 25 | 318 | 64 |
| 2,749 | 3,093 | 4,278 | 3,632 | 4,050 | 4,108 | 4,677 | |
| Total Assets | 5,577 | 5,960 | 6,768 | 6,021 | 6,634 | 7,709 | 8,124 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| 444 | 500 | 704 | 768 | 747 | 1,097 | |
| -409 | -168 | -256 | -574 | -468 | -715 | |
| -735 | -301 | -189 | -152 | -145 | -164 | |
| Net Cash Flow | -700 | 32 | 259 | 42 | 134 | 219 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|
| Debtor Days | 75 | 83 | 107 | 82 | 101 | 102 |
| Inventory Days | 234 | 211 | 293 | 237 | 223 | 225 |
| Days Payable | 142 | 133 | 188 | 184 | 175 | 193 |
| Cash Conversion Cycle | 167 | 161 | 212 | 135 | 148 | 134 |
| Working Capital Days | 69 | 67 | 75 | 96 | 112 | 103 |
| ROCE % | 11% | 22% | 26% | 21% | 19% |
Documents
Announcements
-
Announcement Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations') - Update On USFDA Inspection At API Manufacturing Facility Located At Kurkumbh, Pune, Maharashtra, India
18 Apr - USFDA classifies Kurkumbh API facility inspection as Voluntary Action Indicated (VAI).
-
Intimation Of Change In Email And Website Address Of Registrar And Share Transfer Agent Of The Company
18 Apr - Change in RTA email and website address
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
8 Apr - Confirmation Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2025, received from MUFG Intime India …
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 Apr - Tillomed acquires Manx's pharma portfolio for £19.7 mn.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 Apr - Emcutix partners with WiQo for exclusive skin treatment rights.
Concalls
-
Feb 2025TranscriptPPTREC
-
Nov 2024TranscriptPPT
-
Aug 2024TranscriptPPT
Business Overview:[1][2]
EPL develops, manufactures and markets a broad range of pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. It has a presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV etc. Company has 350+ brands, with a wide network across 70+ countries.